Abbisko Therapeutics
As of the edition of 20 October 2026, Abbisko Therapeutics runs 11 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 7 |
| Status not established | 2 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Mavorixafor | Ends 2031 (exclusivity) | 2 |
| Pimicotinib | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Cancer: 9 trials led
- Bones, joints and muscles: 3 trials led
- Lungs and airways: 2 trials led